Skip to main content
. 2017 Nov 21;28(5):674–683. doi: 10.1111/bpa.12563

Figure 4.

Figure 4

Immunohistochemical features of gliomas with FGFR3‐TACC3 fusion. (A–F,J–L). 200X. (G,H) 100x. (I) 1000X. (M–O) 20X. A. positive Olig2 immunolabeling. B. positive GFAP immunolabeling. C. P53 intense immunolabeling inferior to the threshold of ten percent of tumor cells. D. stellate extravascular CD34 immunolabeling. E. extravascular CD34 immunolabeling as membrane frames. F. positive ramified EMA immunolabeling. G. Ki67 in a grade II tumor. H. Ki67 in a grade IV tumor. I. chromogenic in situ hybridization for centromere of chromosome 12 (red) and MDM2 (black) showed high copy number amplification in case #8. J. intense FGFR3 immunolabeling. K. moderate FGFR3 immunolabeling. L. weak FGFR3 immunolabeling. M. Diffuse intense FGFR3 immunolabeling. N. Diffuse FGFR3 immunolabeling with heterogeneous intensity from weak to intense. O. Focal FGFR3 immunolabeling and negative areas.